PharmGen Science, Inc. (KRX:004720)
South Korea
· Delayed Price · Currency is KRW 3,560.00
-150.00 (-4.04%)
Mar 9, 2026, 3:30 PM KST
PharmGen Science Revenue
PharmGen Science had revenue of 42.88B KRW in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 171.66B, down -0.02% year-over-year. In the year 2024, PharmGen Science had annual revenue of 171.29B with 2.70% growth.
Revenue (ttm)
171.66B
Revenue Growth
-0.02%
P/S Ratio
0.45
Revenue / Employee
759.55M
Employees
226
Market Cap
78.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.29B | 4.51B | 2.70% |
| Dec 31, 2023 | 166.78B | 15.85B | 10.50% |
| Dec 31, 2022 | 150.93B | 41.06B | 37.38% |
| Dec 31, 2021 | 109.87B | 13.25B | 13.72% |
| Dec 31, 2020 | 96.61B | 1.48B | 1.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| Enzychem Lifesciences | 72.17B |
| Humasis | 35.60B |
| Oncocross | 884.68M |
| Ray Co., Ltd. | 97.57B |